Barbara Antonazzo, Vassilios S Vassiliou, Attilio Lauretti, Giuseppe Biondi-Zoccai
{"title":"利用ChatGPT在心血管病学。","authors":"Barbara Antonazzo, Vassilios S Vassiliou, Attilio Lauretti, Giuseppe Biondi-Zoccai","doi":"10.23736/S2724-5683.24.06808-X","DOIUrl":null,"url":null,"abstract":"<p><p>The integration of artificial intelligence (AI) into healthcare is transforming medical practice, and this holds true also for the prevention, diagnosis and treatment of cardiovascular disease in older patients. Large language models (LLMs) like ChatGPT (OpenAI, San Francisco, CA, USA) represent cutting edge AI tools which may offer significant potential to enhance patient care by improving communication, aiding in diagnosis, and assisting in treatment planning. In elderly patients, who often present with complex health profiles and multiple comorbidities, AI can prove particularly beneficial, and it can analyze extensive data to provide personalized, evidence-based recommendations. For instance, ChatGPT can support clinicians in managing polypharmacy by identifying potential drug interactions and suggesting optimal medication regimens, thereby reducing adverse effects. Additionally, AI tools can help overcome therapeutic inertia by prompting timely treatment adjustments, ensuring that elderly patients receive appropriate interventions. However, the successful implementation of AI in cardiogeriatrics requires robust technological infrastructures, a synergistic integration with electronic health records, and careful consideration of ethical and privacy concerns. Ongoing collaboration between technologists and healthcare professionals is essential to address these challenges and fully realize the benefits of AI in enhancing cardiovascular care for the elderly.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Leveraging ChatGPT in cardiogeriatrics.\",\"authors\":\"Barbara Antonazzo, Vassilios S Vassiliou, Attilio Lauretti, Giuseppe Biondi-Zoccai\",\"doi\":\"10.23736/S2724-5683.24.06808-X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The integration of artificial intelligence (AI) into healthcare is transforming medical practice, and this holds true also for the prevention, diagnosis and treatment of cardiovascular disease in older patients. Large language models (LLMs) like ChatGPT (OpenAI, San Francisco, CA, USA) represent cutting edge AI tools which may offer significant potential to enhance patient care by improving communication, aiding in diagnosis, and assisting in treatment planning. In elderly patients, who often present with complex health profiles and multiple comorbidities, AI can prove particularly beneficial, and it can analyze extensive data to provide personalized, evidence-based recommendations. For instance, ChatGPT can support clinicians in managing polypharmacy by identifying potential drug interactions and suggesting optimal medication regimens, thereby reducing adverse effects. Additionally, AI tools can help overcome therapeutic inertia by prompting timely treatment adjustments, ensuring that elderly patients receive appropriate interventions. However, the successful implementation of AI in cardiogeriatrics requires robust technological infrastructures, a synergistic integration with electronic health records, and careful consideration of ethical and privacy concerns. Ongoing collaboration between technologists and healthcare professionals is essential to address these challenges and fully realize the benefits of AI in enhancing cardiovascular care for the elderly.</p>\",\"PeriodicalId\":18668,\"journal\":{\"name\":\"Minerva cardiology and angiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Minerva cardiology and angiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.23736/S2724-5683.24.06808-X\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva cardiology and angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2724-5683.24.06808-X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
人工智能(AI)与医疗保健的融合正在改变医疗实践,这也适用于老年患者心血管疾病的预防、诊断和治疗。像ChatGPT (OpenAI, San Francisco, CA, USA)这样的大型语言模型(llm)代表了尖端的人工智能工具,可以通过改善沟通、辅助诊断和协助治疗计划来提高患者护理的潜力。对于经常出现复杂健康状况和多种合并症的老年患者,人工智能可以证明特别有益,它可以分析大量数据,提供个性化的、基于证据的建议。例如,ChatGPT可以通过识别潜在的药物相互作用并建议最佳用药方案来支持临床医生管理多种药物,从而减少不良反应。此外,人工智能工具可以通过及时调整治疗来帮助克服治疗惯性,确保老年患者接受适当的干预。然而,人工智能在老年心脏病科的成功实施需要强大的技术基础设施,与电子健康记录的协同整合,并仔细考虑道德和隐私问题。技术专家和医疗保健专业人员之间的持续合作对于应对这些挑战并充分实现人工智能在加强老年人心血管护理方面的好处至关重要。
The integration of artificial intelligence (AI) into healthcare is transforming medical practice, and this holds true also for the prevention, diagnosis and treatment of cardiovascular disease in older patients. Large language models (LLMs) like ChatGPT (OpenAI, San Francisco, CA, USA) represent cutting edge AI tools which may offer significant potential to enhance patient care by improving communication, aiding in diagnosis, and assisting in treatment planning. In elderly patients, who often present with complex health profiles and multiple comorbidities, AI can prove particularly beneficial, and it can analyze extensive data to provide personalized, evidence-based recommendations. For instance, ChatGPT can support clinicians in managing polypharmacy by identifying potential drug interactions and suggesting optimal medication regimens, thereby reducing adverse effects. Additionally, AI tools can help overcome therapeutic inertia by prompting timely treatment adjustments, ensuring that elderly patients receive appropriate interventions. However, the successful implementation of AI in cardiogeriatrics requires robust technological infrastructures, a synergistic integration with electronic health records, and careful consideration of ethical and privacy concerns. Ongoing collaboration between technologists and healthcare professionals is essential to address these challenges and fully realize the benefits of AI in enhancing cardiovascular care for the elderly.